Abemaciclib Impurities

Abemaciclib belongs to a group of drugs known as kinase inhibitors.

per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
Abemaciclib D7 Abemaciclib

Abemaciclib D7

DVE001043 N/A
Abemaciclib Impurity 1 Abemaciclib

Abemaciclib Impurity 1

VE0017758 1180132-17-5
Abemaciclib Impurity 2 Abemaciclib

Abemaciclib Impurity 2

VE0017762 1038408-36-4
Abemaciclib Impurity 3 Abemaciclib

Abemaciclib Impurity 3

VE0017759 414881-11-1
Abemaciclib Impurity 4 Abemaciclib

Abemaciclib Impurity 4

VE0017760 N/A
Abemaciclib Impurity 7 Abemaciclib

Abemaciclib Impurity 7

VE0017757 1231930-42-9
Abemaciclib Mesylate Abemaciclib

Abemaciclib Mesylate

VL4990001 1231930-82-7
Abemaciclib-D5 Abemaciclib


DVE001042 1809251-51-1
2-Methanol Abemaciclib Abemaciclib

2-Methanol Abemaciclib

VE0010004 2138499-06-4

Abemaciclib Related Compound

It works by preventing an aberrant protein from signalling cancer cells to proliferate. This aids in slowing or stopping the spread of cancer cells.



  •         “Abemaciclib Approved for Breast Cancer.” National Cancer Institute, Cancer.gov, 26 Oct.2017, www.cancer.gov/news-events/cancer-currents-blog/2017/fda-abemaciclib-breast cancer.
  •          “Abemaciclib: MedlinePlus Drug Information.” Medlineplus.gov, 2022,medlineplus.gov/druginfo/meds/a617049.html.
  • PubChem. “Abemaciclib.” @Pubchem, PubChem, 2023,pubchem.ncbi.nlm.nih.gov/compound/Abemaciclib#:~:text=Abemaciclib%20specifically%20inhibits%20CDK4%20and,and%20inhibiting%20cancer%20cell%20growth..



Abemaciclib is what kind of medication ?

Abemaciclib belongs to the cyclin-dependent kinase (CDK) inhibitor group of medicines. These medications inhibit the function of two proteins, CDK4 and CDK6, which regulate cell division.

How does abemaciclib work in the treatment of breast cancer?

Abemaciclib belongs to a class of drugs known as kinase inhibitors. It works by preventing an inappropriate protein from signalling cancer cells to proliferate. This aids in slowing or stopping the spread of cancer cells.

What is the mechanism of action of Abemaciclib?

Abemaciclib selectively inhibits CDK4 and 6, preventing the phosphorylation of Rb proteins in early G1. Inhibiting Rb phosphorylation limits the CDK-mediated G1-S phase transition, which stops the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell development.